Anti PD-L1 Antibody + Anti CTLA-4 Antibody in Combination With Hormone Therapy in Patients With Hormone Receptor Positive HER2-negative Recurrent or Metastatic Breast Cancer
Condition: Breast Cancer Intervention: Drug: Durvalumab,Tremelimumab,Fulvestrant Sponsor: Kyoto Breast Cancer Research Network Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials